Literature DB >> 22482499

Targeting β-catenin in CML: leukemia stem cells beware!

Maria Kleppe1, Ross L Levine.   

Abstract

In this issue of Cell Stem Cell, Heidel et al. (2012) use genetic and pharmacological approaches to reveal that Wnt/β-catenin signaling is required for leukemic stem cell (LSC) maintenance in chronic myeloid leukemia. They demonstrate that β-catenin inactivation targets imanitib-resistant LSCs in vivo.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22482499     DOI： 10.1016/j.stem.2012.03.006

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  8 in total

1.  Downregulation of ROS1 enhances the therapeutic efficacy of arsenic trioxide in acute myeloid leukemia cell lines.

Authors:  Jun Li
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

2.  DOCK4 promotes loss of proliferation in glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster expression.

Authors:  D N Debruyne; L Turchi; F Burel-Vandenbos; M Fareh; F Almairac; V Virolle; D Figarella-Branger; N Baeza-Kallee; P Lagadec; V Kubiniek; P Paquis; D Fontaine; M-P Junier; H Chneiweiss; T Virolle
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

3.  Apoptosis induction in K562 human myelogenous leukaemia cells is connected to the modulation of Wnt/β-catenin signalling by BHX, a novel pyrazoline derivative.

Authors:  Hanmei Bao; Qing Zhang; Yibo Du; Cai Zhang; Hui Xu; Zhongling Zhu; Zhao Yan
Journal:  Cell Prolif       Date:  2018-01-16       Impact factor: 6.831

Review 4.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

5.  Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.

Authors:  Beatrice Riva; Marco De Dominici; Ilaria Gnemmi; Samanta A Mariani; Alberto Minassi; Valentina Minieri; Paolo Salomoni; Pier Luigi Canonico; Armando A Genazzani; Bruno Calabretta; Fabrizio Condorelli
Journal:  Oncotarget       Date:  2016-12-06

6.  Cordycepin disrupts leukemia association with mesenchymal stromal cells and eliminates leukemia stem cell activity.

Authors:  Shu-Man Liang; Yi-Jhu Lu; Bor-Sheng Ko; Yee-Jee Jan; Song-Kun Shyue; Shaw-Fang Yet; Jun-Yang Liou
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

7.  Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.

Authors:  H Zhou; P Y Mak; H Mu; D H Mak; Z Zeng; J Cortes; Q Liu; M Andreeff; B Z Carter
Journal:  Leukemia       Date:  2017-03-21       Impact factor: 11.528

8.  Cordycepin regulates GSK-3β/β-catenin signaling in human leukemia cells.

Authors:  Bor-Sheng Ko; Yi-Jhu Lu; Wen-Ling Yao; Tzu-An Liu; Shean-Shong Tzean; Tang-Long Shen; Jun-Yang Liou
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.